Payment overview · 2025
General Payments
$512.26
23 reported records · 12 companies
Healthcare provider profile · identity verified
Dawn Dansby
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · ATHENS, TX · NPI 1902276009
Verified facts
What the public records show
CMS Open Payments records show Dawn Dansby received $512.26 in general payments during 2025 across 23 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 18.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Kerendia, Ozempic, Rexulti, Rybelsus, Trelegy Ellipta.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 152 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Mounjaro by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $92.92 | 18.1% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $64.92 | 12.7% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $58.70 | 11.5% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $51.04 | 10.0% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $50.29 | 9.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $42.35 | 8.3% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $33.52 | 6.5% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $31.04 | 6.1% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $27.71 | 5.4% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $21.97 | 4.3% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $19.47 | 3.8% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $18.33 | 3.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $512.26 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $112.39 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $64.92 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $58.70 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $58.70 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $51.04 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $51.04 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $50.29 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $33.52 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $31.04 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $27.71 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $23.57 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $23.57 | 1 | 2025 |
Source payment records
|
|||||
| ETERNA Normalized: eterna |
Device | Abbott Laboratories | $21.97 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.78 | 1 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $18.33 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 60 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 152 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 53 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 111 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 68 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 100 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 67 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
67 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
152 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
68 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
111 | 24 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
100 | 18 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
68 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
60 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 570 | 114 |
| Atorvastatin Calcium | Atorvastatin Calcium | 365 | 95 |
| Lisinopril | Lisinopril | 364 | 88 |
| Pantoprazole Sodium | Pantoprazole Sodium | 364 | 84 |
| Gabapentin | Gabapentin | 297 | 68 |
| Trazodone Hcl | Trazodone Hcl | 243 | 44 |
| Furosemide | Furosemide | 240 | 58 |
| Potassium Chloride | Potassium Chloride | 215 | 41 |
| Sertraline Hcl | Sertraline Hcl | 189 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 186 | 49 |
| Amlodipine Besylate | Amlodipine Besylate | 183 | 49 |
| Ezetimibe | Ezetimibe | 182 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 173 | 43 |
| Duloxetine Hcl | Duloxetine Hcl | 169 | 33 |
| Losartan Potassium | Losartan Potassium | 157 | 39 |
| Metformin Hcl | Metformin Hcl | 155 | 39 |
| Jardiance | Empagliflozin | 152 | 25 |
| Omeprazole | Omeprazole | 150 | 34 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 146 | 44 |
| Metoprolol Succinate | Metoprolol Succinate | 144 | 38 |
| Meloxicam | Meloxicam | 142 | 36 |
| Donepezil Hcl | Donepezil Hcl | 132 | 28 |
| Warfarin Sodium | Warfarin Sodium | 131 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 124 | 47 |
| Alendronate Sodium | Alendronate Sodium | 123 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 115 | 26 |
| Ozempic | Semaglutide | 111 | 24 |
| Buspirone Hcl | Buspirone Hcl | 105 | 26 |
| Ropinirole Hcl | Ropinirole Hcl | 104 | 19 |
| Rybelsus | Semaglutide | 100 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 91 | 29 |
| Mirtazapine | Mirtazapine | 89 | 13 |
| Montelukast Sodium | Montelukast Sodium | 87 | 21 |
| Glipizide | Glipizide | 82 | 21 |
| Spironolactone | Spironolactone | 78 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 70 | 12 |
| Carvedilol | Carvedilol | 69 | 21 |
| Cefuroxime | Cefuroxime Axetil | 69 | 52 |
| Rexulti | Brexpiprazole | 68 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 67 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 67 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 63 | 49 |
| Gemfibrozil | Gemfibrozil | 63 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 63 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 61 | 19 |
| Eliquis | Apixaban | 60 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 60 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 56 | 16 |
| Simvastatin | Simvastatin | 55 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 54 | 11 |
| Aripiprazole | Aripiprazole | 53 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 53 | 44 |
| Kerendia | Finerenone | 53 | suppressed |
| Bupropion Xl | Bupropion Hcl | 50 | 13 |
| Allopurinol | Allopurinol | 47 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 47 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 47 | suppressed |
| Januvia | Sitagliptin Phosphate | 46 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 46 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 45 | 16 |
| Memantine Hcl | Memantine Hcl | 44 | suppressed |
| Estradiol | Estradiol | 42 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 41 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 41 | suppressed |
| Linzess | Linaclotide | 41 | suppressed |
| Methylprednisolone | Methylprednisolone | 38 | 34 |
| Breo Ellipta | Fluticasone/Vilanterol | 37 | suppressed |
| Ibuprofen | Ibuprofen | 37 | suppressed |
| Sucralfate | Sucralfate | 36 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 35 | 14 |
| Sotalol | Sotalol Hcl | 35 | suppressed |
| Atenolol | Atenolol | 34 | suppressed |
| Myrbetriq | Mirabegron | 34 | suppressed |
| Synthroid | Levothyroxine Sodium | 34 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 33 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 33 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 33 | 11 |
| Felodipine Er | Felodipine | 33 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 32 | suppressed |
| Glimepiride | Glimepiride | 32 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Vascepa | Icosapent Ethyl | 31 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 30 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 29 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 29 | 11 |
| Topiramate | Topiramate | 29 | suppressed |
| Ondansetron Odt | Ondansetron | 27 | 13 |
| Famotidine | Famotidine | 26 | suppressed |
| Azithromycin | Azithromycin | 24 | 23 |
| Benztropine Mesylate | Benztropine Mesylate | 24 | suppressed |
| Digoxin | Digoxin | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 23 |
| Glipizide Er | Glipizide | 23 | suppressed |
| Levemir Flexpen | Insulin Detemir | 22 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Progesterone | Progesterone, Micronized | 20 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | 12 |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Carbamazepine | Carbamazepine | 18 | suppressed |
| Mounjaro | Tirzepatide | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Nystatin | Nystatin | 17 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 16 | 14 |
| Valacyclovir | Valacyclovir Hcl | 16 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 15 | 12 |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Colchicine | Colchicine | 14 | 11 |
| Fluconazole | Fluconazole | 14 | 11 |
| Levemir | Insulin Detemir | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 14 | suppressed |
| Xifaxan | Rifaximin | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 13 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Ofloxacin | Ofloxacin | 13 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Valproic Acid | Valproic Acid | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Prednisone | Prednisone | 11 | suppressed |
| Qulipta | Atogepant | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $512.26 · 23 records | Otsuka America Pharmaceutical, Inc. | Auvelity, CAPLYTA, ELIQUIS, ETERNA, General - Therapies, JARDIANCE, Kerendia, NURTEC ODT, OTEZLA, Ozempic, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, Wegovy | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Bayer Healthcare Pharmaceuticals Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error